Follow us on
Search News Archives
Conferences | Events
Lab Bulletin Media Partners
Quotient Bioresearch

Quotient Bioresearch

Quotient Bioresearch

Products

Contact Quotient Bioresearch


If you have not logged into the website then please enter your details below.

All articles from Quotient Bioresearch

  Quotient Clinical Expands Data Sciences Capability

Department moves into enhanced facility and increases headcount in response to continued demand for services

QuotientQuotient Clinical, the Translational PharmaceuticsÂŽ company, a leading provider of early stage and specialist drug development services, today announced the expansion of its Data Sciences function with relocation to a larger office, staying in Edinburgh. The expansion comes in response to growing customer demand for the Data Sciences service....

 

  Quotient Clinical Acquired by Specialist Healthcare Investor GHO Capital

Quotient Clinical the Translational PharmaceuticsŽ company, has announced that it has been acquired by specialist healthcare investor GHO Capital, with financial details of the transaction remaining undisclosed.

Quotient ClinicalQuotient Clinical has brought innovation to the drug development process through its unique Translational PharmaceuticsÂŽ platform, which integrates formulation development, real-time GMP manufacturing and clinical testing. This approach has been proven to accelerate timelines and reduce associated costs, driving overall improvements in R&D productivity. With over 280 employees, the company serves an international customer...

 

  Quotient Bioresearch looks to new horizons at the 5th EBF Open Symposium

Quotient Bioresearch is preparing to head to Barcelona to deliver five presentations and present two posters at the prestigious European Bioanalysis Forum (EBF) Open Symposium, taking place on November 14th to 16th

QuotientWith the recent ÂŁ1.5m expansion to its bioanalytical facility in Cambridgeshire, UK, the forthcoming EBF Symposium provides a perfect opportunity for Quotient scientists to exchange ideas with peers in the broader bioanalytical community...

 

  Quotient discusses Biomarkers and Decision-Making in Drug Development

Earlier this month, over 40 delegates gathered at Quotient Bioresearch’s Bioanalytical Sciences facility in Cambridgeshire for its annual Autumn Seminar

QuotientThis year’s seminar, entitled “Biomarkers and Decision-Making in Drug Development”, included presentations from industry leaders from Biotechnology and Pharmaceutical companies, leading academics in the field and case studies by Quotient scientists...

 

  Quotient Bioresearch Investment in Bioanalytical Facility

Quotient Bioresearch (“Quotient”), the leading provider of early stage and specialist drug development services, has today announced the completion of a £1.5m expansion to its Fordham, Cambridgeshire site

Fordham expansionThe building work took place over the summer and included a new bioanalytical facility with a capacity for 30 mass spectrometers and new laboratories for immunoassay and cell-based work with biopharmaceuticals and biomarkers. The expansion is in response to an increase in demand for Quotient’s services in this area...

 

  Quotient announces completion and publication of a RapidFACT program for Eli Lilly to develop an optimised drug product for new pain medication

Quotient Clinical, part of Quotient Bioresearch ("Quotient") today announced the publication of results, in the journal Pharmaceutical Research, of a RapidFACTTM program conducted for Eli Lilly

Quotient ClinicalThe integrated pharmaceutical development and clinical program was designed to develop an optimal controlled release (CR) formulation for the molecule LY545695 - a new potential medicine for the treatment of persistent pain. The RapidFACT program achieved all of its objectives. An optimised drug product was delivered that matched the target exposure profile, and at a dose reduced by 30% in comparison with the drug product(s) that had been used in the earlier stages of development...

 

  Quotient Bioresearch Expands its Molecular Biology Services Quotient Bioresearch (Quotient), a leading provider of early stage and specialist drug development services, has today announced a significant expansion to its molecular biology service offering. 

QuotientThis service arose from the microbiology group at Quotient (formerly GR Micro), with more than 13 years' experience in molecular characterisation, to support the development of nti-infectives. The integration of microbiology within Quotient's bioanalytical, biomarker and central lab services in 2007 and subsequent investment has broadened the molecular offering available to customers...

 

  Quotient receives final patent approval for its Enterion technology – the industry’s leading clinical technology for investigating drug absorption Quotient_ClinicalQuotient Clinical, part of Quotient Bioresearch ("Quotient") announced today that it has received approval of the final patent for its EnterionTM technology. This completes a portfolio of eight granted patents across North America and Europe, with a lifetime extending through to 2020. The Enterion capsule has been developed to investigate the absorption of drugs from the gastrointestinal (GI) tract.  It is a remote-controlled device that is capable of precisely delivering pharmaceutically relevant drug formulations (both liquids and solids) to specific sites within the GI tract...

 

  Quotient showcases ICHM3 exploratory clinical trials at ASCPT Quotient BioresearchQuotient Clinical, a business unit of Quotient Bioresearch ("Quotient"), will present two significant poster publications at the forthcoming American Society for Clinical Pharmacology and Therapeutics (ASCPT) meeting to be held on March 12th to 17th in Maryland, USA...

 

  Quotient Bioresearch secures investment for next phase of growth Quotient Bioresearch Quotient Bioresearch ("Quotient") has today announced a management buyout financed by TA Associates, the existing private equity shareholder. Terms of the buyout were not disclosed. Quotient is a UK-based provider of outsourced development services, employing over 500 people and serving pharmaceutical and life science customers on a global basis. It has built a broad and innovative service portfolio, principally targeted at the early stages of drug development, and based upon its chemistry, metabolism, bioanalytical and clinical capabilities...

 

  Quotient’s PK/PD Seminar leads the way QuotientLeading academics and delegates from around the world gathered last week for Quotient Bioresearch's Autumn Seminar into the latest approaches in the use of PK, PD and PK/PD modelling in drug development. The seminar, held at Quotient Bioresearch's Bioanalytical Sciences facility in Cambridgeshire, UK saw over 60 delegates from the pharmaceutical industry meet to hear a series of presentations and take part in lively debate with key academics and industry thought-leaders...

 

  Quotient Bioresearch Announces First Use of Bruker Maldi Biotyper for Bacterial Identification Quotient Bioresearch Quotient Bioresearch has today announced its adoption of Bruker's MALDI Biotyper for bacterial identification, following a successful year-long trial. The announcement, made at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) where Quotient presented a series of posters, places the company in a unique position as the first GLP laboratory to adopt the technology for routine bacterial identification as part of its portfolio of services for antimicrobial development...

 

  Quotient announces agreement with Phico Therapeutics and first application of RapidFACT for nasal delivery Quotient_ClinicalQuotient Clinical, a business unit of Quotient Bioresearch (Quotient), today announced an agreement with UK-based biotech, Phico Therapeutics (Phico). Quotient will undertake a RapidFACTTM program to optimise nasal delivery of Phico's SASPjectTM PT1.2, an antibiotic protein technology that offers a new approach for the treatment of serious life-threatening bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA)...

 

  Quotient announces new RapidFACT program with MediGene Quotient ClinicalQuotient Clinical, a business unit of Quotient Bioresearch (Quotient), today announced an agreement with MediGene AG (MediGene), the German biotechnology company, to undertake a RapidFACTTM formulation development and clinical testing program on RhuDexÂŽ, subject to ethical and Medicines and Healthcare products Regulatory Agency (MHRA) approval...

 

  Quotient Bioresearch sparks debate on bioanalysis Quotient BioresearchThe challenges and solutions for the bioanalysis industry were top of the agenda for last week's exclusive bioanalysis seminar organised by Quotient Bioresearch in Munich, Germany. The seminar was attended by representatives from pharmaceutical and biotechnology organisations across Europe and featured debates and panel discussions from leading industry speakers on new techniques and hot topics including the latest industry guidelines...

 

  Quotient Clinical expands clinical capacity in response to customer adoption of its Synthesis-to-Clinic human ADME service Quotient ClinicalQuotient Clinical, a business unit of Quotient Bioresearch ("Quotient"), today announced the completion of a major expansion of its clinical facilities in Nottingham, UK. Bed capacity has been increased by 50 per cent and a dedicated sample processing laboratory for human ADME studies has been incorporated. The new facilities have been inspected and approved for use by the UK regulatory authority, the Medicines and Healthcare products Regulatory Agency (MHRA), and have been awarded Supplementary Accreditation...

 

  Quotient Bioresearch and KWS BioTest partner to deliver end-to-end anti-infectives screening Quotient BioresearchLeading drug development service providers, Quotient Bioresearch Ltd. and KWS BioTest Ltd., have today announced a new strategic partnership to provide a novel co-ordinated approach to support the discovery and development of new antimicrobial agents...

 

  Quotient Bioresearch deploys GxPi’s x-docs ‘Server’ EDMS to Manage Vital Documents for the Drug Development Process GxPi x docs Server EDMSGxPi, specialists in providing compliant IT solutions to the Life Sciences sector, announced today that their x-docsTM ‘Server' electronic document management solution (EDMS) has been successfully installed and implemented by Quotient Bioresearch across 4 sites in the UK.

 

  Quotient Clinical and Bend Research Announce Collaboration Quotient ClinicalBend Research Inc. a leading independent drug formulation development and manufacturing company, and Quotient Clinical, a business unit of Quotient Bioresearch a leading developer of compounds through clinical trials, announced today a nonexclusive collaboration that can speed the advance of compounds to clinical trials and expand options for drug delivery.

 

  Quotient Bioresearch to Highlight Integrated Early Stage Drug Development Platforms at FIP Pharmaceutical Sciences World Congress 2010 Quotient Bioresearch, a leading provider of early and specialist drug development services, will be highlighting its unique Translational PharmaceuticsTM and Synthesis-to-ClinicTM platforms at FIP Pharmaceutical Sciences World Congress 2010 in association with AAPS Annual Meeting & Exposition, New Orleans, 14-18 November, on booth #3019

 

  Quotient Bioresearch Celebrates Official Opening of New State-of-the-Art Radiochemistry Facility Quotient Bioresearch, a leading provider of early stage and specialist drug development services to pharmaceutical, biotechnology and medical device clients worldwide, has officially opened its new, state-of-the-art radiochemistry facility in Cardiff, UK, with a ceremony including a VIP opening by the First Minister of Wales, Carwyn Jones

 

  New State-of-the-Art Radiochemistry Facility Fully Operational Quotient Bioresearch, a leading provider of early stage and specialist drug development services to pharmaceutical, biotechnology and medical device clients worldwide, today announced that its new, state-of-the-art radiochemistry facility in Cardiff, UK is fully operational and that shipments of radiolabelled products have commenced.

 

  Quotient Bioresearch Presents Comprehensive Drug Development Capabilities via New Company Website Quotient Bioresearch ("Quotient"), a leading provider of early stage and specialist drug development services to pharmaceutical, biotechnology and medical device clients worldwide, announces the launch of its new company website,